<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOPAMINE HYDROCHLORIDE</span><br/>(doe'pa-meen)<br/><span class="topboxtradename">Dopastat, </span><span class="topboxtradename">Intropin, </span><span class="topboxtradename">Revimine <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha- and beta-adrenergic agonist (sympathomimetic)</span><br/><b>Prototype: </b>Epinephrine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg/mL, 80 mg/mL, 160 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Naturally occurring neurotransmitter and immediate precursor of norepinephrine. Major cardiovascular effects produced by direct
         action on alpha- and beta-adrenergic receptors and on specific dopaminergic receptors in mesenteric and renal vascular beds.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Positive inotropic effect on myocardium increases cardiac output with increase in systolic and pulse pressure and little or
         no effect on diastolic pressure. Improves circulation to renal vascular bed by decreasing renal vascular resistance with resulting
         increase in glomerular filtration rate and urinary output.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To correct hemodynamic imbalance in shock syndrome due to MI (cardiogenic shock), trauma, endotoxic septicemia (septic shock),
         open heart surgery, and CHF.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acute renal failure; cirrhosis; hepatorenal syndrome; barbiturate intoxication.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pheochromocytoma; tachyarrhythmias or ventricular fibrillation. Safe use during pregnancy (category C), lactation, or children
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with history of occlusive vascular disease (e.g., Buerger's or Raynaud's disease); cold injury; diabetic endarteritis,
         arterial embolism.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Shock</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 25 mcg/kg/min increased gradually up to 2050 mcg/kg/min if necessary<br/><br/><span class="indicationtitle">Renal Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 25 mcg/kg/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span>  Dilute just prior to administration.  Dilute each ampule in one of the following: D5W, D5/NS, D5/LR, D5/0.45% NaCl, NS. Dilute 200 mg ampule in 250 mL, 500 mL, or 1000 mL IV solution to yield 800 mcg/mL, 400 mcg/mL, or 200 mcg/mL, respectively.
                  Dilute 400 mg ampule in 250 mL, 500 mL, or 1000 mL IV solution to yield 1600 mcg/mL, 800 mcg/mL or 400 mcg/mL, respectively. Dilute 800 mg ampule in 250 mL, 500 mL, or 1000 mL IV solution to yield 3200 mcg/mL, 1600 mcg/mL or 800 mcg/mL, respectively. Consult package information for other dilutions. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Continuous:</span>   Infusion rate is based on body weight. Infusion rate and guidelines for adjusting rate relative changes in blood pressure are prescribed by physician. Microdrip and other reliable metering device should be used for accuracy of flow rate. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> <b> Sodium bicarbonate,</b> <b>aminophylline,</b> <b>amphotericin B,</b> <b>ampicillin,</b> <b>cephalothin,</b> <b>penicillin G.</b> <span class="incompattype"> Y-site:</span> <b> Acyclovir,</b> <b>aminophylline,</b> <b>amphotericin B,</b> <b>sodium bicarbonate.</b>
</p>
<ul>
<li>Correct hypovolemia, if possible, with either whole blood or plasma before initiation of dopamine therapy.</li>
<li>Monitor infusion continuously for free flow, and take care to avoid extravasation, which can result in tissue sloughing and
                     gangrene. Use a large vein of the antecubital fossa.
                  </li>
<li>Antidote for extravasation: Stop infusion promptly and remove needle. Immediately infiltrate the ischemic area with 510
                     mg phentolamine mesylate in 1015 mL of NS, using syringe and fine needle.
                  </li>
<li>Protect dopamine from light. Discolored solutions should not be used.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution for 24 h at 2°15° C (36°59° F) or 6 h at room temperature 15°30°
            C.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> <span class="speceff-common">Hypotension,</span> ectopic beats, <span class="speceff-common">tachycardia,</span> anginal pain, palpitation, vasoconstriction (indicated by disproportionate rise in diastolic pressure), cold extremities;
      less frequent: <span class="speceff-life">aberrant conduction</span>, bradycardia, widening of QRS complex, elevated blood pressure. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">CNS:</span> Headache. <span class="typehead">Skin:</span> Necrosis, tissue sloughing with extravasation, <span class="speceff-life">gangrene</span>, piloerection. <span class="typehead">Other:</span> Azotemia, dyspnea, dilated pupils (high doses). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Dopamine may modify test response when histamine is used as a control for <span class="alt">intradermal skin tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">mao inhibitors</span>, <span class="classification">ergot alkaloids</span>, <b>furazolidine</b> increase alpha-adrenergic effects (headache, hyperpyrexia, hypertension); <b>guanethidine,</b> <b>phenytoin</b> may decrease dopamine action; <span class="classification">beta blockers</span> antagonize cardiac effects; <span class="classification">alpha blockers</span> antagonize peripheral vasoconstriction; <b>halothane,</b> <b>cyclopropane</b> increase risk of hypertension and ventricular arrhythmias. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  Duration: Distribution: Widely distributed; does not cross bloodbrain barrier. <span class="typehead">Metabolism:</span> Inactive in the liver, kidney, and plasma by monoamine oxidase and COMT. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor blood pressure, pulse, peripheral pulses, and urinary output at intervals prescribed by physician. Precise measurements
            are essential for accurate titration of dosage.
         </li>
<li>Report the following indicators promptly to physician for use in decreasing or temporarily suspending dose: Reduced urine
            flow rate in absence of hypotension; ascending tachycardia; dysrhythmias; disproportionate rise in diastolic pressure (marked
            decrease in pulse pressure); signs of peripheral ischemia (pallor, cyanosis, mottling, coldness, complaints of tenderness,
            pain, numbness, or burning sensation).
         </li>
<li>Monitor therapeutic effectiveness. In addition to improvement in vital signs and urine flow, other indices of adequate dosage
            and perfusion of vital organs include loss of pallor, increase in toe temperature, adequacy of nail bed capillary filling,
            and reversal of confusion or comatose state.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>